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ABSTRACT 
 
ETV6-related thrombocytopenia (ETV6-RT) is an autosomal dominant thrombocytopenia that has been 
recently identified in a few families and has been suspected to predispose to hematological malignancies. 
To gain further information on this disorder, we searched for ETV6 mutations in the 130 families with 
inherited thrombocytopenia of unknown origin from our cohort of 274 consecutive pedigrees with familial 
thrombocytopenia. We identified 20 ETV6-RT patients from 7 pedigrees. They have 5 different ETV6 
variants, including three novel mutations affecting the highly conserved E26 transformation-specific 
domain. The relative frequency of ETV6-RT resulted 2.6% in the whole case series and 4.6% among the 
families with known forms of inherited thrombocytopenia. The degree of thrombocytopenia and bleeding 
tendency of ETV6-RT patients were mild, but 4 subjects developed B-cell acute lymphoblastic leukemia 
during childhood, resulting in a significantly increased incidence compared to the general population. 
Clinical and laboratory findings did not identify any peculiar defects that can be used to suspect this 
disorder by routine diagnostic workup. However, at variance with most inherited thrombocytopenias, 
platelet size was not enlarged. In vitro studies revealed that patients’ megakaryocytes have defective 
maturation and impaired proplatelet formation. Moreover, ETV6-RT platelets have reduced ability to 
spread on fibrinogen. Since also the dominant thrombocytopenias due to mutations in RUNX1 and 
ANKRD26 are characterized by normal platelet size and predispose to hematological malignancies, we 
suggest that mutation screening of ETV6, RUNX1 and ANKRD26 should be performed in all the subjects with 
autosomal dominant thrombocytopenia and normal platelet size. 
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INTRODUCTION 
 
Until the end of the last century, only a few forms of inherited thrombocytopenia (IT) were known, all of 
them extremely rare and characterized by severe bleeding tendency. Since then, knowledge of ITs has 
greatly improved and we presently know at least 26 disorders caused by mutations in 30 genes.
1,2 
 This 
advancement of knowledge revealed that most patients with ITs have only mild or moderate 
thrombocytopenia, with trivial bleeding episodes or no bleeding at all. However, it also became apparent 
than many patients are exposed to the threat of acquiring additional defects that worsen their quality of 
life or can even be fatal. Subjects with MYH9-related disease are predisposed to proteinuric nephropathy 
evolving into end stage renal failure, those with congenital amegakaryocytic thrombocytopenia always 
develop bone marrow aplasia, while patients with ANKRD26-related thrombocytopenia (ANKRD26-RT) or 
familial platelet disorder with predisposition to acute myeloid leukemia (AML) due to RUNX1 mutations 
(FPD/AML) have increased risk of AML and myelodysplastic syndromes (MDS). Thus, bleeding is no longer 
the unique problem of IT patients.   
 
In 2015, four independent studies showed that mutations in the gene ETV6 are responsible for a new form 
of IT and suggested that ETV6-related thrombocytopenia (ETV6-RT) predisposes to acute lymphoblastic 
leukemia (ALL)
3-6
. However, only a few families have been reported so far and the clinical and laboratory 
features of ETV6-RT remain poorly defined.  
 
In order to gain further information on this disorder, we screened for ETV6 mutations 130 consecutive 
unrelated propositi with IT of unknown origin and identified 7 affected families. Two of these pedigrees 
have been briefly reported in a previous paper.
4
 Here we describe the features of 20 affected subjects,  
who form the largest cohort of ETV6-RT patients collected so far. As these patients were identified by 
screening a wide series of consecutive, unselected probands with familial thrombocytopenia, we could 
estimate the relative frequency of ETV6-RT among ITs and the risk of hematological malignancies 
associated with this condition. By reporting in details the clinical and laboratory features of these patients, 
we provide the tools to suspect this disorder in the routine diagnostic workup of probands with ITs. Finally, 
we discuss the pathogenesis of ETV6-RT by investigating for the first time megakaryocytes (Mks) 
differentiated from hematopoietic progenitors of patients, and by the functional characterization of ETV6-
RT platelets.  
 
METHODS 
 
Patients 
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From 2003 to 2014, we analyzed at the IRCCS Policlinico San Matteo Foundation of Pavia (Italy) 274 
consecutive unrelated probands with familial thrombocytopenia. By the application of a well-defined 
diagnostic algorithm for ITs,
1 
we made a molecular diagnosis in 144 of these families, whereas 130 
probands remained without a definite diagnosis as they did not fit the criteria for any known IT. These 130 
consecutive propositi with IT of unknown origin have been screened for mutations in ETV6. Whenever ETV6 
mutations were identified, the available relatives of probands have been investigated.  
 
Bleeding tendency was measured according to the International Society on Thrombosis and Haemostasis 
(ISTH) bleeding assessment tool (BAT) score.
7
 
 
The institutional review board of the San Matteo Foundation approved the study and all subjects or their 
legal guardians signed written informed consent in accordance with the Declaration of Helsinki. 
 
Mutation screening and RT-PCR 
 
Genomic DNA and RNA were extracted from peripheral blood. The ETV6 gene was analyzed using Sanger 
and whole exome sequencing. Methods of mutation screening and RT-PCR are detailed in the 
supplementary information.  
 
Bioinformatic tools and analysis of the structures 
 
The bioinformatic tools used to evaluate missense variants and methods of analysis of ETV6 structure are 
reported in supplementary information.  
 
Basic blood cell studies  
 
Blood cell counts were evaluated by electronic counters. Parameters relative to platelet diameter were 
measured by software-assisted image analysis on blood smears as reported.
8 
The following previously 
defined parameters were computed: mean platelet diameter (MPD), platelet diameter distribution width 
(PDDW), platelet diameter large cell ratio (PDLCR), and platelet diameter small cell ratio (PDSCR).
8
 The 
percentage of large platelets has been also estimated empirically, as previously reported
8 
and detailed in 
supplementary information. Surface expression of platelet glycoproteins (GPs) was investigated by flow 
cytometry as reported, whereas platelet aggregation was evaluated by the densitometric method of Born.
9
 
The used antibodies and platelet agonists are listed in supplementary information.  
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Platelet activation 
 
Platelet activation in response to ADP or TRAP was investigated by flow cytometry as reported.
10
 The 
protocol is described in details in supplementary information.  
 
Platelet adhesion and spreading 
 
Platelet adhesion and spreading on the subendothelium components of the extracellular matrix type I 
collagen, von Willebrand Factor, or fibrinogen, were investigated as previously described
11,12 
and as 
detailed in supplementary information.  
 
Investigation of megakaryocytes   
 
Mks were differentiated in vitro from peripheral blood CD45
+
 cells as previously reported.
13,14
 
Morphological analysis of Mks was performed by phase-contrast and fluorescence microscopy, while the 
percentage of fully differentiated Mks and Mk ploidy at the end of the culture were investigated by flow 
cytometry.
14,15 
Proplatelet yields were evaluated both in suspension and in adhesion on fibrinogen at the 
end of the culture, as previously described.
13,16
 Methods are reported in supplementary information.
 
 
Statistical analysis 
 
Data are presented as mean and SD or range. Statistical comparisons were performed by two-tailed 
Student t test. Incidences of hematologic malignancies (per 100 000 person years) together with their exact 
95% confidence intervals (95%CI) were computed.  
 
RESULTS 
 
Mutation screening 
 
The analysis of the ETV6 gene allowed us to identify 5 different heterozygous variants in 7 unrelated 
pedigrees. Two variants (c.641C>T/p.P214L and c.1252A>G/ p.R418G+p.N385Vfs*7) were previously 
reported in two families (Figure 1A, families B and G).
4
 The remaining three novel variants are two missense 
alterations and one deletion. 
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The two missense variants, c.1105C>T (p.R369W) and c.1138T>A (p.W380R) segregate in the affected 
family members and are not present in healthy relatives (Figure 1A). They are absent in public genomic 
databases, such as dbSNP (www.ncbi.nlm.nih.gov/SNP), 1000 genomes (www.1000genomes.org), and 
Exome Aggregation Consortium (www.exac.broadinstitute.org). Multiple-sequence alignment indicated 
that they affect highly conserved amino acid residues (data not shown). They are predicted to be 
deleterious for protein function according to different tools (Supplementary Table S1). Moreover, the CADD 
scores were 26.1 and 23.1 for p.R369W and p.W380R, respectively. Both mutations map in the E26 
transformation-specific (ETS) domain which is in the C-terminal half of the protein (residues 337-421). 
Analysis of the coordinates of the ETS domain of ETV6 (2DAO) (numbered in pdb C8 and L112, so that R369 
and W380 correspond to R39 and W50) shows that W380 is well buried in the hydrophobic core and 
surrounded by a number of hydrophobic residues, such as L341 and M394 (L11 and M64 in the structure) 
(Figure 1E). W380 is also close to the side chains of H383 and K384 (H53 and K54). Its substitution to an 
arginine will greatly destabilize the structure by creating both an uncompensated cavity in the hydrophobic 
core and an electrostatic repulsion with nearby positively charged residues. Residue R369 is well exposed 
on the protein surface and is predicted to form an electrostatic interaction with the spatially nearby E361 
(E31). Its substitution with a tryptophan could destabilize the fold by abolishing this interaction. 
Alternatively, this residue could be implicated in protein-protein interactions. In this case, its substitution 
with a much bulkier and uncharged residue could be deleterious.  
 
The c.1153-1_1165del deletion variant removes the last "G" nucleotide of intron 6 and the first 13 
nucleotides of exon 7. To provide the effect of this deletion, we carried out RT-PCR on the three affected 
individuals of family F. Sequencing analysis of the altered 721 bp product showed skipping of exon 7 
(r.1153_1253del/p.N385Vfs*7; Figure 1B) resulting in truncation of the ETS domain. Since the 721 bp band 
is fainter than the wild type product (822 bp), we cannot exclude that the alternatively spliced mRNA is 
partially degraded. Inspection of the intron 6/exon 7 genomic boundary reveals repeats that are likely to be 
involved in non-allelic homologous recombination leading to micro deletions/duplications (Figure 1C). 
 
The 7 families reported in figure 1A formed our cohort of 20 affected individuals who have been studied for 
the phenotypic characterization of ETV6-RT. 
 
Clinical picture 
 
A mild bleeding tendency was present in 12 patients, whereas 8 subjects had no significant bleeding 
diathesis (Table 1). More common bleeding symptoms were petechiae, ecchymoses, gum bleeding, 
epistaxis, and menorrhagia. Thrombocytopenia was discovered in the adulthood in 5 patients, whereas it 
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was identified at birth in 6 patients because of the family history of low platelet count. One patient (E/I-3) 
was initially misdiagnosed with immune thrombocytopenia, and received steroids and underwent 
splenectomy at age 9 years without increase of his platelet count. Ten patients underwent 17 surgeries and 
6 had tooth extractions without excessive bleeding. Four women gave birth to 6 children, three vaginally 
and three by cesarean section. Prophylactic platelet transfusion was deemed necessary to cover one 
vaginal delivery. Excessive bleeding (800 mL) was reported in another woman (patient F/I-2) who had given 
birth vaginally. We have no information on her platelet count and function at the time of the delivery; 
however, it is interesting to note that she presented defective platelet response to low doses of collagen 
and ADP when she was investigated at our institution (see below).  
 
Unilateral polydactyly was observed in one patient, mitral valve prolapse in two subjects, and renal ectopia 
in one. So, no recurrent extra-hematological abnormalities have been identified. 
 
Four patients from 4 families developed B-cell ALL (common ALL in three cases, not better defined in one) 
during childhood. Conventional cytogenetic analysis resulted normal in three cases, while patient E/II-1 had 
hyperdiploid ALL; the search for the ETV6-AML1 transcript was performed in one patient (E/II-1) with 
normal findings. The incidence of ALL in our case series was 731.3 per 100 000 (95%CI, 274.5-1948.4), while 
it is 1.4 per 100 000 in the general population according to the National Cancer Institute.
17
 Three patients 
obtained remission after conventional chemotherapy, and one after hematopoietic stem cell 
transplantation (HSCT) from unrelated donor. The patient E/I-3, who had a history of isolated 
thrombocytopenia since childhood (Table 1), at age 37 developed increased hemoglobin level (19.0 gr/dL, 
hematocrit 56%), with mild leukocytosis and thrombocytosis. The JAK2V617F mutation was identified and a 
diagnosis of polycythemia vera was made.  
 
A history of non-hematological neoplasms was present in three patients. The patient B/II-1 had breast 
fibroadenoma at age 35 and meningioma at age 42. The patient G/I-2 had breast carcinoma at age 49, 
while the patient F/II-2 had breast fibroadenoma at age 14.  
 
Blood cell counts and peripheral blood film examination 
 
Table 1 reports the blood cell counts obtained at the last examination for 18 patients, and at the last 
available examination before the development of polycythemia vera and before HSCT for the patients E/I-3 
and E/II-1, respectively. Eleven patients had less than 100 x 10
9
 platelets/L and only one less than 50 x 
10
9
/L. For most patients we could obtain the platelet counts measured at different ages prior to the 
evaluation for this study (Supplementary Table S2). Patients presented some fluctuations in their platelet 
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counts over time, however, none of them showed a definite trend toward improvement or worsening of 
thrombocytopenia during life.  
 
Mean platelet volume (MPV) was slightly reduced in 4 cases and normal in the other 14 evaluable patients  
(Table 1). Peripheral blood film examination in 16 patients showed that MPD was similar to that of healthy 
subjects, confirming that average platelet size is consistently normal in ETV6-RT patients (Table 2). We 
found very mild but significant increases of PDDW and PDLCR, which indicate that a mild platelet 
anisocytosis and a slightly increased proportion of large platelets were frequent features of the investigated 
patients. In agreement with previous findings,
8 
the empirical measurement of the percentage of platelets 
larger than half an erythrocyte gave similar results to the assessment of PDLCR by image analysis (data not 
shown). Conversely, the increased mean PDDW detected by image analysis did not correspond to increased 
mean platelet distribution width (PDW) values obtained by automated cell counts (not shown).  
 
Mild anemia has been observed in one patient with iron deficiency (A/II-1). Mean corpuscular volume 
(MCV) was reduced in this subject, increased without any apparent cause in five subjects, and within the 
normal range in the remaining patients. White blood cell count was normal in all the cases. 
 
In vitro platelet studies 
 
Platelet aggregation. Among the 11 investigated patients, the three patients from family F had mildly 
reduced platelet aggregation after stimulation with collagen 4 µg/mL and ADP 5 µM, while individual C/II-1 
showed a slightly reduced response to ristocetin 1.5 mg/mL (Table 3). However, all patients had completely 
normal responses to higher concentrations of these agonists (collagen 20 µg/mL, ADP 20 µM, ristocetin 3 
mg/mL, data not shown), indicating that, if present, the aggregation defects were mild.  
 
Platelet flow cytometry. As shown in Table 3, flow cytometry performed in 11 patients did not identify any 
consistent defect of the major GPs of the platelet surface. 
 
Platelet activation.  Overall, the surface expression of activated GPIIb-IIIa and P-selectin and the reduction 
of GPIbα upon stimulation of platelets with ADP or TRAP, were not significantly different in 11 ETV6-RT 
patients with respect to controls (Supplementary Figure 1). A mild reduction of activated GPIIb-IIIa 
expression (52 to 65% of controls) after stimulation with TRAP was observed in three patients.  
 
Platelet adhesion and spreading. In vitro adhesion of platelets from 7 patients to subendothelium 
components of the extracellular matrix was not different from that of controls. However, the ability of 
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ETV6-RT platelets to spread on fibrinogen was consistently and significantly reduced, while spreading on 
collagen and von Willebrand Factor was normal (Table 4). 
 
In vitro culture of megakaryocytes and assessment of proplatelet formation  
 
In vitro culture of Mks was performed in 8 patients and 8 healthy subjects. After 14 days of culture, 
expression levels of the major Mk differentiation surface markers (GPIIIa, GPIIb and GPIbα) were similar to 
those of healthy controls (Figures 2A and 2B). Conversely, Mk ploidy was significantly lower in patients than 
controls (Figure 2C), and this was paralleled by differences in Mk diameters (Figure 2D). The analysis of 
proplatelets formation revealed that Mks from patients elongated proplatelet shafts of shorter length and 
with decreased number of branches compared to controls. Further, the percentage of proplatelet-forming 
Mks was significantly reduced. In contrast, the size of proplatelet tips was similar to that of controls (data 
not shown). Similar results were obtained with Mks in suspension (Figures 3A and 3B) and in adhesion on 
fibrinogen (Figures 3C and 3D). 
 
DISCUSSION 
 
This  study reports the molecular and phenotypic characterization of 7 families with germline mutations in 
ETV6. In addition to the variants previously reported,
4 
we identified three novel alterations, which are likely 
to be pathogenetic. The two novel missense variants (p.R369W and p.W380R) segregated within the 
families, are absent in public genomic databases, and are expected to be deleterious for protein function by 
bioinformatic tools and analysis of protein conformational structure. ETV6 is a modular protein which 
contains a PNT and an ETS domain sandwiched between regions of potential intrinsically unstructured 
nature. Both p.R369W and p.W380R affect the ETS domain, a conserved region that directly interacts with 
DNA consensus sequences. We have shown that the role of W380 is structural, being surrounded by 
hydrophobic residues in the domain hydrophobic core. Its substitution to an arginine will thus greatly 
destabilize the domain structure. Residue R369 is involved in an electrostatic interaction and possibly in 
protein-protein interactions. 
It is important to note that the somatic p.R369W has been previously associated with chronic 
myelomonocytic leukemia (CMML), colorectal cancer, and childhood leukemia.
5,6
 Moreover, Zhang et al. 
previously reported one ETV6-RT pedigree carrying a different germline missense variant affecting the 
same residue (p.R369Q). Similarly to our patients with the p.R369W, the subjects with p.R369Q presented 
mild thrombocytopenia and normal platelet morphology.
6
 Among the 8 members of the p.R369Q pedigree, 
one CMML at age 82 and one colorectal cancer at age 43 were reported,
6
 whereas we did not observe 
neoplasms in our p.R369W patients at a median age at evaluation of 30 years. Finally, both p.R369Q and 
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p.R369W have been associated with genetic predisposition to childhood ALL.
3
 These observations suggest 
that arginine 369 is a mutational hot spot.  
Regarding the c.1153-1_1165del variant, RT-PCR demonstrated that it affects the splicing process leading to 
skipping of exon 7 (p.N385Vfs*7). The same alternative splicing was also caused by the c.1153-5_1153-1del 
mutation,
5
 which, as c.1153-1_1165del, is likely to derive form non-allelic homologous recombination 
between repetitive sequences present at the intron 6/exon 7 boundary. The skipping of exon 7 is also 
determined by the c.1252A>G substitution.
4
 Affecting the second to last nucleotide of exon 7, this allele is 
associated with both correctly (p.R418G) and alternatively (p.N385Vfs*7) spliced mRNA.
4
 
Of the 10 different mutant forms identified so far in ETV6-RT families, the p.P214L is the only one which 
does not affect the ETS domain (Figure 1D), but instead alters a less conserved central domain that 
interacts with several transcription repressors further controlling expression of the target genes. Contrary 
to the other germline mutations, which are mainly private, this substitution was responsible for ETV6-RT in 
4 of the 14 families characterized so far, indicating that it represents another potential mutational hot spot.  
 
ETV6 is a transcriptional repressor involved in the embryonic development and hematopoietic regulation.
18
 
In particular, animal studies suggested that ETV6 has two independent roles in mouse hematopoiesis: on 
the one hand it is required for survival of hematopoietic stem cells, on the other it promotes the late 
phases of megakaryopoiesis. Interest in ETV6 greatly increased at the end of the last century after 
demonstration that its deregulation due to rearrangement, fusion or deletion is involved in hematologic 
malignancies.
19,20
 Moreover, somatic mutations in ETV6 were recently found in a variety of hematologic 
neoplasm, including AML, T and B cell ALL, mixed-phenotype acute leukemia, MDS, chronic lymphocytic 
leukemia and chronic myelogenous leukemia.
21
 Even more recently, targeted sequencing of ETV6 in 4405 
childhood ALL cases identified 31 germline variants potentially related to leukemia in 35 cases.
3
  Based on 
this evidence, it is not surprising that the 4 studies that identified ETV6-RT in 41 subjects from 9 families 
found that 16 patients (39%) had hematological malignancies, with 12 patients (29%) developing ALL.
3-6
 Of 
note, 11 of 12 subjects with ALL were children. The other observed blood neoplasms in ETV6-RT patients 
were mixed-phenotype acute leukemia, multiple myeloma, MDS and CMML. 
 
We found that 4 of 20 consecutive patients with ETV6-RT (20%) developed ALL during childhood, thus 
confirming that early leukemic transformation is a major risk of these patients. Moreover, we observed that 
one patient developed JAK2 positive polycythemia vera at age 37, supporting the previous hypothesis that 
ETV6-RT predisposes not only to ALL, but also to other blood neoplasms. The frequency of hematologic 
malignancies is lower in our study than in the previous ones (25% versus 39%). This is explained by the fact 
that, in the previous investigations,
3-6
 the occurrence of hematologic malignancies was one of the criteria 
for the recruitment of patients, while we examined a series of consecutive, unselected patients with IT of 
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unknown origin. This approach appears more suitable to provide a reliable estimation of the incidence of 
hematologic neoplasms among ETV6-RT patients. Of course, the analysis of a larger series of patients is 
needed to confirm this figure.  
 
Similarly to this study, we previously searched for ANKRD26 mutations a large series of unselected patients 
and revealed that 10 of 118 (8%) subjects with ANKRD26-RT had developed myeloid malignancies.
22
  Thus, 
hematological malignancies seem much more frequent in ETV6-RT than ANKRD26-RT. The risk of 
malignancies appears even higher in FPD/AML, since over 40% of patients had myeloid neoplasms.
23
  
However, as discussed for ETV6-RT, also RUNX1 mutational screening was generally performed in pedigrees 
with hematological malignancies,
24
  and it is therefore likely that the incidence of transformation has been 
overestimated. However, each patient with an IT caused by mutations in ETV6, RUNX1 or ANKRD26 has a 
relevant risk of hematological malignancies, and recognizing these patients is required not only to provide 
effective genetic counseling and appropriate follow-up, but also to give an appropriate treatment to 
patients who developed blood neoplasms and need HSCT. In fact, as shown in different disorders 
predisposing to myeloid malignancies,
25
 the use of an affected family member as the donor would entail 
the risk of developing malignancies once again.  
 
ETV6-RT is a relatively frequent form of IT. In fact, in our series of 274 consecutive propositi, ETV6-RT was 
identified in 7 families and had, therefore, a relative prevalence of 2.6% in the whole case series, and of 
4.6% in the series of probands with known ITs (7/151). In our cohort, the frequency of ETV6-RT was lower 
only to that of monoallelic Bernard-Soulier syndrome (BSS, 12.2% in the whole series), MYH9-related 
disease (11.4%), ANKRD26-RT (9.4%), and biallelic BSS (5.7%). Since most of our patients with monoallelic 
BSS had the Ala156Val mutation of GPIbα (Bolzano mutation), which is exclusive of the Italian population,
26
 
it is expected that the relative frequency of ETV6-RT is even higher in other countries. 
 
Our study did not identify any peculiar feature that can be used to raise the suspicion of ETV6-RT by routine 
diagnostic workup and the diagnosis remains therefore difficult. In particular, a previous investigation, 
which reported also 5 patients who have been re-evaluated for this study, suggested that red blood cell 
(RBC) macrocytosis is a feature of the ETV6-RT phenotype.
4
 In that investigation, the percentage of patients 
with increased MCV was 40%,
4
 whereas it resulted 25% in the present study. Concerning the 5 patients 
reported in both studies, RBC macrocytosis had been found in two individuals by the previous examination 
but was not confirmed by the present evaluation. Of note, the absolute MCV values were similar in the two 
studies (mean 94.5 fL with SD 3.8 vs. mean 93.3 fL with SD 8.9) and the discrepancy in the percentage of 
patients with RBC macrocytosis resulted from the different upper limits of normal range used in the two 
investigation (95 fL in the previous study and 98 fL in the present one, according to the normal ranges of 
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the different laboratories). On the whole, these findings indicate that RBC macrocytosis is present in a 
minority of patients with ETV6-RT, and suggest that it may be inconstantly found in the same patients over 
time. Thus, RBC macrocytosis seems to have a limited diagnostic value to recognize this condition. 
Moreover, we did not identify any distinguishing defect of major platelet GPs or in vitro platelet 
aggregation. Also evaluation of peripheral blood films did not reveal any morphological abnormality, except 
for mild platelet anisocytosis. However, at variance with most ITs, MPD and MPV were consistently normal 
in ETV6-RT, and it is just the normal size of platelets that should raise suspicion of this condition in subjects 
with an autosomal dominant thrombocytopenia. In fact, the other dominant ITs with this feature are 
FDP/AML, ANKRD26-RT, and CYCS-RT. Of note, CYCS-RT is a very rare condition described so far in only two 
pedigrees,
1
 whereas the other two disorders are more frequent and, as ETV6-RT, predispose to 
hematologic malignancies. Thus, we suggest that all subjects with a dominant IT and normal platelet size 
should be tested for mutations in ETV6, RUNX1, and ANKRD26, in order to recognize one of these 
predisposition syndromes.  
 
The psychological impact of receiving a diagnosis of ETV6-RT, as well as of FPD-AML or ANKRD26-RT, should 
be carefully considered by physicians. We suggest that each patient, before undergoing diagnostic workup 
for thrombocytopenia of suspected genetic origin, is correctly informed about the possibility to receive a 
diagnosis that implicates the risk of malignancies, and has the chance to state in advance if he wants to 
receive information about the risk of neoplasms, for himself as well as for his progeny. 
 
Our study investigated for the first time in vitro megakaryopoiesis of ETV6-RT patients. We showed that 
ETV6 pathogenetic variants impair Mk maturation, as demonstrated by the production of smaller Mks with 
decreased ploidy. These immature Mks showed an impaired ability to extend fully developed proplatelets, 
providing an explanation for thrombocytopenia. These findings seem consistent with the results of the 
studies in mice, which suggested a role for ETV6 in terminal Mk maturation,
18
 and with the findings 
obtained with Mk differentiated from human CD34
+
 cells transduced with some ETV6 variants.
4 
We also had 
the possibility to study in detail the function of platelets in a substantial number of patients. Although we 
did not identify any consistent defect of in vitro platelet aggregation, activation and adhesion, we found 
that the ability of platelets to spread on fibrinogen was reduced in all the investigated patients. As the 
platelet expression of GPIIb-IIIa was normal, this finding suggests that mutations in the ETV6 transcription 
factor alter the expression of one or more proteins involved in the GPIIb-IIIa-mediated platelet outside-in 
signalling after interaction with fibrinogen. Moreover, this defect could contribute to the bleeding diathesis 
observed in some ETV6-RT individuals. In fact, although the degree of bleeding was always mild, the 
proportion of patients with spontaneous bleeding (60%) appeared globally high with respect to the very 
mild degree of thrombocytopenia. 
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In conclusion, our study showed that monoallelic ETV6 mutations cause a relatively frequent form of IT and 
confirmed that affected subjects have mild bleeding tendency but propensity to hematological 
malignancies, in particular ALL. Since ETV6-RT is one of the few autosomal dominant forms of IT without 
platelet macrocytosis, the screening for ETV6 mutations is recommended in all patients with these 
characteristics. 
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Table 1. Main characteristics of the investigated patients. 
Family/ 
Individual 
ETV6 mutation
2 
Age
3
, y/ 
Gender 
Age at  
diagnosis
4
, y  
ISTH BAT 
score
5 
Platelets, 
x10
9
/L 
MPV, 
fL
6 
MPD, 
µm
7 
Hgb, 
g/dL 
MCV, 
fL
8 
WBC,  
x10
9
/L 
Neutrophils 
x10
9
/L 
Hematological 
malignancies 
A/I-1 c.641C>T 
p.Pro214Leu 
57/M 30 3 115 8.8 2.44 14.6 99 7.13 4.9  
A/II-1 20/F birth 7 59 8.6 2.24 10.4 68 4.98 2.3  
A/II-2 27/F birth 3 82 8.2 2.23 13.6 98 5.5 3.39 Common ALL at age 7 
B/I-2
1 
43/F 14   0 115 10 2.82 11.1 88 5.02 1.75 B-cell ALL at age 15 
B/II-1
1 
15/M birth   3 66 10.4 2.89 14.0 91 5.36 1.18  
B/II-2
1 
18/F 2   0 44 10.1 3.26 13.1 97 4.04 1.42  
C/I-1 c.1105C>T 
p.Arg369Trp 
48/M 38  3 112 na 2.73 15.4 103 6.3 4  
C/II-1 13/M 3    0 87 na 2.53 14.1 86 3.84 1.81  
D/I-1 53/M 47   0 110 8.4 2.42 13.7 97 5.4 2.84  
D/II-1 7/F 1   0 109 9.2 2.28 12.6 79 6.82 1.87  
E/I-1 c.1138T>A  
p.Trp380Arg 
37/F 8    0 105 8.1 na 14.2 97 7.50 5.2  
E/I-3 42/M 5   4 55
9
 9.1
9
 na 14.9
9
 94
9
 8.0
9
 6.1
9
 JAK2V617F+ PV at age 37 
E/I-4 45/M 20   0 93 7.9 na 16.9 101 8.30 4.24  
E/II-1 20/M 4    2 60
10
  8.0
10
 2.73
10
 14.8
10
 86
10
 5.11
10
 1.97
10
 Common ALL at age 7 
E/II-3 13/M birth   4 99 7.4 na 14.0 90 6.15 2.45  
F/I-2 c.1153-1_1165del 
r.1153_1253del 
p.Asn385Valfs*7 
49/F 7    2 105 8.9 2.55 13.4 107 7.11 4.4  
F/II-1 12/F birth   1 57 8.6 2.40 14.2 97 6.59 4  
F/II-2 17/F birth   2 70 8.7 2.36 14.4 97 8.24 5.3 Common ALL at age 3 
G/I-2
1 
c.1252A>G 
p.Arg418Gly + 
p.Asn385Valfs*7 
51/F 20   0 101 7.6 3.17 13.6 97 4.71 2.02  
G/II-1
1 
28/M 3    2 101 7.8 2.99 15.9 97 5.3 2.39  
 
Notes: 
1 
Previously reported patients.
 2 
Nucleotide A of the ATG translation initiation start site of the ETV6 cDNA in GenBank sequence NM_001987.4 is 
indicated as nucleotide +1. Novel germline mutations are in bold. 
3
 Age at the last evaluation: the blood parameters and bleeding score reported here have 
been measured at the last evaluation, unless otherwise specified. 
4 
Age at diagnosis of thrombocytopenia. 
5
 International Society on Thrombosis and 
Haemostasis (ISTH) bleeding assessment tool (BAT) score was calculated as previously reported (reference 7). 
6 
Normal range: 8-13.4 fL. 
7
Normal range: 1.9-3.4 
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μm. 8Normal range: 82-98 fL. 9Parameters measured at the last available examination before the development of PV (age 35). 10Parameters measured before 
chemotherapy and HSCT for the development of ALL. Abbreviations: na: not available; ALL: acute lymphoblastic leukemia; PV: polycythemia vera.
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Table 2. Parameters of platelet diameters measured on peripheral blood films in investigated patients. 
 
 No.
1
 
MPD, μm 
mean (SD) 
PDDW, μm 
mean (SD) 
PDLCR, % 
mean (SD) 
PDSCR, % 
mean (SD) 
Family A 3 2.30 (0.12) 2.57 (0.06) 8.27 (1.77) 5.87 (3.19) 
Family B 3 2.99 (0.24) 2.97 (0.21) 12.3 (4.75) 1 (0.86) 
Family C 2 2.63 (0.31) 2.75 (0.49) 7 (4.24) 1.25 (1.06) 
Family D 2 2.35 (0.10) 2.10 (0.14) 4.5 (4.95) 5.5 (3.53) 
Family E 1 2.73 2.9 8.5 1 
Family F 3 2.44 (0.10) 2.57 (0.35) 8.83 (4.07) 3.16 (1.25) 
Family G 2 3.08 (0.13) 3.15 (0.49) 13 (7.07) 0.5 (0.71) 
      
Total ETV6-RT patients 16 2.63 (0.17) 2.70 (0.29)* 9.23 (4.47)* 2.85 (1.77) 
Healthy subjects
2
 55 2.49 (0.32) 2.18 (0.58) 3.64 (4.93) 4.35 (5.9) 
 
Notes: 
1
 Number of investigated subjects. 
2
 Values of healthy subjects previously measured in a cohort of 
55 healthy volunteers (reference 8).
  
*p <0.01 with respect to healthy subjects.  
 
Abbreviations: MPD, mean platelet diameter. PDDW, platelet diameter distribution width = difference 
from the 2.5
th
 to the 97.5
th
 percentile of platelet diameter distribution. PDLCR, platelet diameter large cell 
ratio = proportion of platelets larger than the 97.5
th
 percentile of MPD of healthy subjects (3.9 µm). PDSCR, 
platelet diameter small cell ratio = proportion of platelets smaller than the 2.5
th
 percentile of the MPD of 
healthy subjects (1.6 µm) (reference 8). 
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Table 3. In vitro platelet aggregation and surface expression of major platelet glycoproteins in investigated patients.  
 
 Platelet aggregation, maximal extent, % 
1 
- mean (range) Surface expression of platelet glycoproteins, % of controls - mean (range) 
Family No. of 
investigated 
subjects 
Collagen,  
4 mcg/mL 
ADP,  
5 μM 
Ristocetin,  
1.5 mg/mL 
No. of 
investigated 
subjects 
GPIbα (SZ2) GPIX (SZ1) GPIIb (P2) 
A 2 80 (71-89) 75 (66-84) 88 (76-100) 2 131 (130-132) 130 (116-144) 91 (85-97) 
B 2 80 (74-87) 81 (77-85) 80 (68-93) 3 98.7 (98-99) 99 (98-100) 98.7 (97-100) 
C 2 71 (69-73) 57 (44-70) 67 (57-77) 2 147.5 (143-152) 126 (122-130) 108 (94-122) 
F 3 54 (50-56) 37 (35-39) 100 (100-100) 2 117.5 (110-125) 125 (121-129) 127.5 (118-137) 
G 2 78 (67-90) 82 (78-87) 88 (77-100) 2 159.5 (136-165) 101 (89-113) 85 (78-92) 
 
Note: 
1
 Normal ranges: collagen 66-88; ADP 43-76; ristocetin 67-90. 
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Table 4. In vitro platelet interaction with subendothelium molecules in 7 ETV6-RT patients.  
 
 Platelet adhesion and spreading , % of controls - mean (SD) 
No. of adhering 
platelets  
% of spread 
platelets  
Surface area covered by 
platelets  
Fibrinogen 102.9 (27.6) 51.5 (33.5)* 61 (28.5)* 
Collagen 107.2 (45.1) 103.6 (41.7) 122.4 (29.3) 
von Willebrand Factor 80.4 (36.5) 103.8 (41.5) 120.7 (22.7) 
 
Note: * p <0.01 with respect to controls 
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FIGURE LEGENDS 
 
Figure 1. Mutations identified in the ETV6 gene. (A) Pedigrees of families enrolled in this study carrying 
different mutations as indicated (in bold novel mutations). Nucleotide numbering reflects the ETV6 cDNA 
with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (RefSeq 
NM_001987.4). Therefore, the initiation codon is residue 1 in the amino acid sequence. Families B and G 
have been previously reported (reference 4). (B) RT-PCR in affected members (I-2, II-1, and II-2) of family F 
to determine the consequence of the c.1153-1_1165del mutation on splicing. C+, wild type control; C-, 
negative control. The analysis shows two fragments, the wild type (822 bp) and the exon 7 skipping (721 
bp) products. (C) The deletion of the 14 bp (gAACAGAACAAACA) of c.1153-1_1165del is likely due to non-
allelic homologous recombination between the two GAACAAACA repeats located at the intron 6 and exon 7 
boundary. (D) Domain structure of ETV6 (XP_011518909.1) based on Pfam annotation at 
http://www.ncbi.nlm.nih.gov/gene/2120 (PNT, N-terminal pointed domain; ETS, C-terminal DNA binding 
domain), with mutations identified in ETV6, already reported or identified in this study (top). The number 
of families carrying each mutation are in brackets. Mutations leading to skipping of exon 7 are boxed. (E) 
Structural modeling of the ETS domain with residues R369 (blue) and W380 (green) affected by the 
p.R369W and p.W380R mutations. 
 
Figure 2. Normal differentiation but decreased ploidy by ETV6-RT megakaryocytes. Hematopoietic 
progenitors from peripheral blood samples of healthy controls (CTRL) and patients (ETV6-RT) were 
differentiated in vitro into megakaryocytes in presence of TPO, IL6 and IL11. (A) Representative 
immunofluorescence staining of plasma membrane GPIIIa in CTRL and ETV6-RT megakaryocytes 
(red=GPIIIa; blue=nuclei; scale bar=20 µm). (B) Flow cytometry analysis of GPIIb and GPIbα expression 
revealed comparable percentage of double stained population in CTRL and ETV6-RT at the end of the 
culture. (C) Ploidy of megakaryocytes at the end of the culture was significantly reduced in cells of ETV6-RT 
patients (*p<0.05). (D) Diameters of megakaryocytes were also significantly lower in ETV6-RT patients (total 
number of analyzed cells: 1,100, *p<0.01). 
 
Figure 3. Aberrant proplatelet formation by ETV6-RT megakaryocytes (A) Representative light microscopy 
analysis of proplatelet formation and structure from controls (CTRL, i) and patients (ETV6-RT, ii-v) 
megakaryocytes cultured for 16 hours in suspension (scale bar=50 µm). (B) The percentage of proplatelet 
forming megakaryocytes was calculated as the number of megakaryocytes displaying at least one 
filamentous pseudopod with respect to total number of round megakaryocytes per analyzed field 
(*p<0.01). (C) Representative fluorescence microscopy analysis of proplatelet formation and structure from 
CTRL (i-ii) and ETV6-RT (iii-vi) megakaryocytes cultured for 16 hours in adhesion on fibrinogen. Pictures 
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clearly show defective proplatelet elongation in ETV6-RT (red=β1-tubulin; blue=nuclei; scale bar=30 µm). 
(D) The percentage of proplatelet forming megakaryocytes was calculated as the number of β1-tubulin+ 
cells displaying at least one pseudopod with respect to total number of round megakaryocytes per analyzed 
field (*p<0.01).  
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